Studio di efficacia e sicurezza di nipocalimab per adulti con polineuropatia demielinizzante infiammatoria cronica (CIDP)
Studio di fase 2/3, multistadio, multicentrico, randomizzato, in doppio cieco, a gruppi paralleli controllato con placebo per valutare l'efficacia e la sicurezza di nipocalimab somministrato ad adulti con polineuropatia demielinizzante infiammatoria cronica (CIDP)
The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
- Fase 3
Accesso esteso
Accesso esteso
Temporaneamente non disponibile
- Disponibile: l'accesso esteso è attualmente disponibile per questo trattamento sperimentale e i pazienti che non partecipano allo studio clinico potrebbero essere in grado di accedere al farmaco, al biologico o al dispositivo medico in fase di studio.
- Non più disponibile: l'accesso esteso era disponibile per questo intervento in precedenza, ma non è attualmente disponibile e non sarà disponibile in futuro.
- Temporaneamente non disponibile: l'accesso esteso non è attualmente disponibile per questo intervento, ma dovrebbe esserlo in futuro.
- Approvato per il marketing: l'intervento è stato approvato dalla Food and Drug Administration degli Stati Uniti per l'uso da parte del pubblico.
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Study Contact
- Numero di telefono: 844-434-4210
- Email: Participate-In-This-Study1@its.jnj.com
Luoghi di studio
-
-
-
Buenos Aires, Argentina, C1199ABB
- Attivo, non reclutante
- Hospital Italiano de Buenos Aires
-
Buenos Aires, Argentina, C1428AQK
- Reclutamento
- Instituto Fleni
-
Buenos Aires, Argentina, C1428
- Completato
- Hospital Gral Agudos Ignacio Pirovano
-
Rosario, Argentina, 2900
- Reclutamento
- INECO Neurociencias Orono
-
-
-
-
-
Melbourne, Australia, 3004
- Completato
- The Alfred Hospital
-
Parkwood, Australia, 4215
- Completato
- Gold Coast University Hospital
-
-
-
-
-
Ottawa, Canada, K1N 6N5
- Reclutamento
- The Ottawa Hospital Ottawa NeuroMuscular Centre
-
-
-
-
-
Hradec Králové, Cechia, 500 05
- Attivo, non reclutante
- Fakultni nemocnice Hradec Kralove
-
Ostrava, Cechia, 708 52
- Completato
- Fakultni Nemocnice Ostrava
-
Pardubice, Cechia, 53203
- Completato
- Pardubicka krajska nemocnice a s
-
-
-
-
-
Beijing, Cina, 100191
- Completato
- Peking University Third Hospital
-
Beijing, Cina, 100034
- Completato
- Peking University First Hospital
-
Beijing, Cina, 100053
- Attivo, non reclutante
- Xuanwu Hospital ,Capital Medical University
-
Beijing, Cina, 100070
- Attivo, non reclutante
- Beijing Tiantan Hospital, Capital Medical University
-
Changchun, Cina, 130021
- Attivo, non reclutante
- The First Hospital of Jilin University
-
Changsha, Cina, 410008
- Completato
- Xiangya Hospital Central South University
-
Changsha, Cina, 410008
- Attivo, non reclutante
- The Third Xiangya Hospital of Central Sourth University
-
Chengdu, Cina, 610072
- Completato
- Sichuan Provincial Peoples Hospital
-
Chifeng, Cina, 024000
- Completato
- Chifeng Municipal Hospital
-
Fuzhou, Cina, 350001
- Attivo, non reclutante
- Fujian Medical University Union Hospital
-
Guangzhou, Cina, 510080
- Attivo, non reclutante
- The First Affiliated Hospital Sun Yat sen University
-
Jinan, Cina, 250012
- Attivo, non reclutante
- Qilu Hospital of Shandong University
-
Jinan, Cina, 250014
- Completato
- Qianfoshan hospital of Shandong Province
-
Nanchang, Cina, 330006
- Attivo, non reclutante
- The First Affiliated Hospital of NanChang University
-
Shanghai, Cina, 200336
- Completato
- Tong Ren Hospital Shanghai Jiao Tong University school of medicine
-
Shanghai, Cina, 200040
- Attivo, non reclutante
- Huashan Hospital Fudan University
-
Wuhan, Cina, 430023
- Completato
- Renmin Hospital of Wuhan University
-
Xi'an, Cina, 710032
- Completato
- Tangdu hospital the Fourth Military Medical
-
Xi'an, Cina, 710075
- Attivo, non reclutante
- Xi 'an GaoXin Hospital
-
-
-
-
-
Floridablanca, Colombia, 681004
- Completato
- Fundación Cardiovascular de Colombia - Instituto del Corazón Floridablanca
-
Medellín, Colombia, 50021
- Attivo, non reclutante
- Instituto Neurológico de Colombia
-
-
-
-
-
Seoul, Corea del Sud, 05030
- Completato
- Konkuk University Medical Center
-
Seoul, Corea del Sud, 02447
- Completato
- Kyunghee University Medical Center
-
Seoul, Corea del Sud, 135-710
- Completato
- Samsung Medical Center
-
-
-
-
-
Bordeaux, Francia, 33000
- Completato
- CHU Bordeaux
-
Bron, Francia, 69699
- Completato
- Hospices Civils de Lyon HCL
-
Le Kremlin-Bicêtre, Francia, 94270
- Attivo, non reclutante
- Hopital de Bicetre
-
Marseille, Francia, 13385
- Attivo, non reclutante
- Hopital de la Timone
-
Nice, Francia, 06000
- Attivo, non reclutante
- Hopital PASTEUR
-
Nîmes, Francia, 30029
- Attivo, non reclutante
- CHU Nimes Hopital Caremeau
-
Paris, Francia, 75013
- Completato
- Hopital de la Pitie Salpetriere
-
Paris, Francia, 75019
- Completato
- Fondation Adolphe de Rothschild Hospital
-
Strasbourg, Francia, 67200
- Attivo, non reclutante
- CHRU Strasbourg
-
-
-
-
-
Berlin, Germania, 13347
- Attivo, non reclutante
- Judisches Krankenhaus Berlin
-
Bochum, Germania, 44791
- Completato
- St. Josef-Hospital, Ruhr-Universität Bochum
-
Halle, Germania, 6120
- Attivo, non reclutante
- Städtisches Krankenhaus Martha-Maria Halle-Dölau gGmbH
-
Hanover, Germania, 30625
- Attivo, non reclutante
- Medizinische Hochschule Hannover
-
Leipzig, Germania, 4103
- Completato
- Universitaetsklinikum Leipzig
-
Potsdam, Germania, 14471
- Completato
- St Josefs Krankenhaus Potsdam Sanssouci
-
-
-
-
-
Asahikawa, Giappone, 070-0901
- Attivo, non reclutante
- National Hospital Organization Asahikawa Medical Center
-
Bunkyō City, Giappone, 113 8519
- Attivo, non reclutante
- Institute of Science Tokyo Hospital
-
Chiba, Giappone, 260-8677
- Completato
- Chiba University Hospital
-
Hamamatsu, Giappone, 430-8558
- Attivo, non reclutante
- Seirei Hamamatsu General Hospital
-
Isehara, Giappone, 259-1193
- Attivo, non reclutante
- Tokai University Hospital
-
Kobe, Giappone, 650 0047
- Completato
- Kobe City Medical Center General Hospital
-
Kodaira-shi, Giappone, 187-8551
- Attivo, non reclutante
- National Center of Neurology and Psychiatry
-
Koshigaya, Giappone, 343-8555
- Attivo, non reclutante
- Saitama Medical Center
-
Kumamoto, Giappone, 860-8556
- Completato
- Kumamoto University Hospital
-
Nagoya, Giappone, 466-8560
- Attivo, non reclutante
- Nagoya University Hospital
-
Nagoya, Giappone, 455-8530
- Attivo, non reclutante
- Chubu Rosai Hospital
-
Osaka Sayama Shi, Giappone, 589 8511
- Completato
- Kindai University Hospital
-
Sendai, Giappone, 983-8520
- Attivo, non reclutante
- National Hospital Organization Sendai Medical Center
-
Shimotsuga Gun, Giappone, 321 0293
- Completato
- Dokkyo Medical University Hospital
-
Shinjuku-ku, Giappone, 162-8666
- Completato
- Tokyo Women's Medical University Hospital
-
Tenri, Giappone, 632-0015
- Completato
- Tenri Hospital
-
Toon-shi, Giappone, 791-0295
- Completato
- Ehime University Hospital
-
Toyama, Giappone, 930-0194
- Completato
- Toyama University Hospital
-
Ube, Giappone, 755-8505
- Completato
- Yamaguchi University Hospital
-
-
-
-
-
Athens, Grecia, 12462
- Reclutamento
- Attikon General Hospital of Athens
-
Athens, Grecia, 11527
- Completato
- Papageorgiou General Hospital Of Thessaloniki
-
Pátrai, Grecia, 26504
- Completato
- Patras University Hospital
-
Thessaloniki, Grecia, 54636
- Reclutamento
- Ahepa Hospital Aristotle University of Thessaloniki
-
-
-
-
-
Catania, Italia, 95123
- Completato
- Azienda Ospedaliero-Universitaria Policlinico di Catania
-
Genova, Italia, 16132
- Completato
- Azienda Ospedaliera Universitaria San Martino di Genova
-
Milan, Italia, 20144
- Completato
- Casa di Cura del Policlinico
-
Milan, Italia, 20133
- Completato
- Istituto Neurologico Carlo Besta
-
Naples, Italia, 80131
- Attivo, non reclutante
- Azienda Ospedaliera di Rilievo Nazionale A Cardarelli
-
Orbassano, Italia, 10043
- Completato
- Aou San Luigi Gonzaga
-
Pavia, Italia, 27100
- Completato
- Fondazione Istituto Neurologico Casimiro Mondino
-
Roma, Italia, 00168
- Completato
- Fondazione Policlinico Universitario A Gemelli IRCCS
-
Rozzano, Italia, 20086
- Completato
- IRCCS Istituto Clinico Humanitas
-
-
-
-
-
Monterrey, Messico, 64710
- Completato
- i Can Oncology Center
-
Tlalnepantla, Messico, 54055
- Reclutamento
- Clinical Research Institute S.C.
-
-
-
-
-
Chorzów, Polonia, 41 500
- Completato
- Centrum Medyczne
-
Krakow, Polonia, 30 539
- Completato
- Specjalistyczne Gabinety Lekarskie
-
Lublin, Polonia, 20 093
- Completato
- Prywatny Gabinet Lekarski
-
Poznan, Polonia, 61 731
- Attivo, non reclutante
- Clinical Research Center sp z o o MEDIC R s k
-
-
-
-
-
Almada, Portogallo, 2805-267
- Attivo, non reclutante
- Hospital Garcia de Orta
-
Braga, Portogallo, 4710-243
- Completato
- Hospital de Braga
-
Porto, Portogallo, 4200 319
- Attivo, non reclutante
- Centro Hospitalar de Sao Joao Epe
-
-
-
-
-
Birmingham, Regno Unito, B15 2TH
- Completato
- University Hospitals Birmingham NHS Foundation Trust
-
Devon, Regno Unito, EX2 5DW
- Completato
- Royal Devon & Exeter Hospital
-
Glasgow, Regno Unito, G514TF
- Attivo, non reclutante
- NHS Greater Glasgow and Clyde
-
London, Regno Unito, NW3 2QG
- Completato
- Royal Free Hospital
-
Sheffield, Regno Unito, S10 2 JF
- Attivo, non reclutante
- Sheffield Teaching Hospitals NHS Foundation Trust
-
-
-
-
-
Alicante, Spagna, 03010
- Attivo, non reclutante
- Hosp. Gral. Univ. de Alicante
-
Barcelona, Spagna, 8035
- Completato
- Hosp Univ Vall D Hebron
-
Bilbao, Spagna, 48013
- Attivo, non reclutante
- Hosp. Univ. de Basurto
-
Donostia / San Sebastian, Spagna, 20014
- Completato
- Hosp. Univ. Donostia
-
Madrid, Spagna, 28040
- Completato
- Hosp. Clinico San Carlos
-
Seville, Spagna, 41009
- Attivo, non reclutante
- Hosp. Virgen Macarena
-
-
-
-
Colorado
-
Centennial, Colorado, Stati Uniti, 80112
- Attivo, non reclutante
- IMMUNOe Health and Research Centers
-
-
Florida
-
Coral Springs, Florida, Stati Uniti, 33067
- Completato
- Healthcare Innovations Institute Inc
-
Maitland, Florida, Stati Uniti, 32751
- Completato
- Neurology Associates PA
-
Miami, Florida, Stati Uniti, 33136
- Attivo, non reclutante
- ALS Center at the University of Miami
-
-
Georgia
-
Augusta, Georgia, Stati Uniti, 30912
- Completato
- Augusta University
-
-
Kansas
-
Kansas City, Kansas, Stati Uniti, 66160
- Completato
- University of Kansas Medical Center
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21287
- Completato
- Johns Hopkins Hospital
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02111
- Completato
- Boston Clinical Trials
-
-
Michigan
-
Royal Oak, Michigan, Stati Uniti, 48073
- Completato
- Beaumont Hospital Royal Oak
-
-
Missouri
-
Kansas City, Missouri, Stati Uniti, 64128
- Completato
- Kansas City Veterans Affairs Medical Center
-
-
New York
-
New York, New York, Stati Uniti, 10032
- Completato
- The Neurological Institute of New York
-
Patchogue, New York, Stati Uniti, 11772
- Completato
- South Shore Neurologic Associates - Patchogue
-
-
North Carolina
-
Charlotte, North Carolina, Stati Uniti, 28204
- Completato
- The Neurological Institute, PA
-
-
Ohio
-
Cleveland, Ohio, Stati Uniti, 44195
- Attivo, non reclutante
- Cleveland Clinic Main Campus
-
-
Texas
-
Austin, Texas, Stati Uniti, 78756
- Completato
- Austin Neuromuscular Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, Stati Uniti, 53215
- Attivo, non reclutante
- Advocate Health - Aurora St. Luke's Medical Center
-
-
-
-
-
Kaohsiung City, Taiwan, 88301
- Completato
- Kaohsiung Chang Gung Memorial Hospital
-
Taipei, Taiwan, 100
- Attivo, non reclutante
- National Taiwan University Hospital
-
Taipei, Taiwan, 111
- Attivo, non reclutante
- Shin Kong Wu Ho Su Memorial Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Adults greater than or equal to (>=) 18 years of age at the time of consent and as applicable, must also meet the legal age of consent in the jurisdiction in which the study is taking place
- Diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) according to criteria of the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) 2021, progressing or relapsing forms. CIDP diagnosis to be adjudicated by independent committee during screening period
- Inflammatory Neuropathy Cause and Treatment (INCAT) disability score between 2 and 9 at the Run-In Baseline visit for participants entering Run-In, or Stage A Baseline visit for participants directly entering Stage A. Participants with an INCAT score of 2 at trial entry must have this score exclusively from the leg disability score
- Fulfilling any of the following treatment conditions: a) Currently treated with oral corticosteroids (CS) less than or equal to (<=) 20 milligrams (mg)/day; or b) Currently treated with pulsed CS, and/or intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin (SCIg) and the participant is willing to discontinue no later than the run-in baseline visit; or c) Currently treated with oral CS greater than (>) 20 mg/day and the participant is willing to taper to <=20 mg/day during the run-in period; or d) Without previous treatment (treatment naive); or treatment with CS and/or IVIg or SCIg discontinued at least 3 months prior to screening (untreated)
- Active disease as determined by CIDP Disease Activity Status (CDAS) score >= 3
- Other protocol-defined inclusion criteria will apply
Exclusion Criteria:
- Has a history of severe and/or uncontrolled hepatic (example, viral/alcoholic/autoimmune hepatitis/cirrhosis and/or metabolic liver disease), gastrointestinal, renal, pulmonary, cardiovascular, psychiatric, neurological or musculoskeletal disorder, hypertension and/or any other medical or uncontrolled autoimmune disorder(s) (example, diabetes mellitus) or clinically significant abnormalities in screening laboratory that, might interfere with the participants full participation in the study, or might jeopardize the safety of the participant or the validity of the study results
- Pure sensory CIDP or chronic immune sensory polyradiculopathy (CISP) (EAN/PNS definition)
- Any other disease that could better explain the participant's signs and symptoms, such as significant persisting neurological deficits from stroke or central nervous system (CNS) trauma or peripheral neuropathy from another cause such as connective tissue disease or systemic lupus erythematosus
- Polyneuropathy of other causes, including the following: Multifocal motor neuropathy (MMN); Monoclonal gammopathy of uncertain significance with antimyelin associated glycoprotein (anti-MAG) immunoglobulin M (IgM) antibodies; Hereditary motor neuropathy; Hereditary neuropathy with liability to pressure palsies (HNPP); Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change syndromes; Lumbosacral radiculoplexus neuropathy; Polyneuropathy most likely due to diabetes mellitus; Polyneuropathy most likely due to systemic illnesses; Drug- or toxin-induced polyneuropathy Note: A concomitant polyneuropathy of other causes (example, a mild, stable diabetic polyneuropathy) is not necessarily exclusionary if chronic inflammatory demyelinating polyneuropathy (CIDP) is confirmed as the main diagnosis, as determined by the investigator and confirmed by the adjudication committee
- Has known allergies, hypersensitivity, or intolerance to nipocalimab or its excipients
- Other protocol-defined exclusion criteria will apply
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Nipocalimab
Participants in Stage A (Open-label) will receive a loading dose of nipocalimab (Dose 1) intravenous (IV) infusion on Day 1, followed by nipocalimab (Dose 2) IV infusion once every 2 weeks (q2w) from Week 2 to Week 12. Participants who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive nipocalimab (Dose 2) IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first. |
Nipocalimab will be administered intravenously.
Altri nomi:
|
|
Comparatore placebo: Placebo
Participants receiving nipocalimab in Stage A and who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive placebo IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first. |
Placebo will be administered intravenously. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Stage B: Time to First Occurrence of a Relapse Event
Lasso di tempo: Up to 52 weeks
|
Stage B time to first occurrence of a relapse event will be reported. |
Up to 52 weeks
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Stage A: Time to Initial Confirmed Evidence of Clinical Improvement (ECI)
Lasso di tempo: 12 weeks
|
Time to initial confirmed ECI will be reported. |
12 weeks
|
|
Stage A: Percentage of Responders as Determined by ECI
Lasso di tempo: 12 weeks
|
Stage A percentage of responders as determined by ECI will be reported. |
12 weeks
|
|
Stage A: Change from Baseline Over Time in Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale Score
Lasso di tempo: Baseline to 12 weeks
|
Change from Stage A baseline over time in adjusted INCAT disability scale score will be reported. The INCAT disability scale is a clinician-rated assessment that measures activity limitation and degree of functional disability. The INCAT scale is an ordinal scale scored from 0 to 10, with higher scores indicating more disability. |
Baseline to 12 weeks
|
|
Stage A: Change from Stage A Baseline Over Time in Medical Research Council (MRC) Muscle Grading Scale Sum Score
Lasso di tempo: Baseline to 12 weeks
|
Change from Stage A baseline over time in MRC muscle grading scale sum score will be reported. The MRC muscle grading scale is a clinician-rated outcome that provides a strength rating (on a scale from 0 [no visible contraction] to 5 [normal]) in 6 muscles collected bilaterally: deltoid, biceps, wrist extensors, iliopsoas, quadriceps, tibialis anterior. Lower scores indicate greater impairment. |
Baseline to 12 weeks
|
|
Stage A: Change from Baseline Over Time in Inflammatory Rasch-Built Overall Disability Scale (I-RODS) Centile Score
Lasso di tempo: Baseline to 12 weeks
|
Change from Stage A baseline over time in I-RODS centile score will be reported. The I-RODS comprises of 24 items representing common daily activities that address upper and lower limb disability and range in difficulty from very easy to very difficult. Lower scores indicate greater activity and social participation limitations. |
Baseline to 12 weeks
|
|
Stage A: Change from Baseline Over Time in Mean Grip Strength (Dominant Hand)
Lasso di tempo: Baseline to 12 weeks
|
Change from Stage A baseline over time in mean grip strength (dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Baseline to 12 weeks
|
|
Stage A: Change from Baseline Over Time in Mean Grip Strength (Non-Dominant Hand)
Lasso di tempo: Baseline to 12 weeks
|
Change from Stage A baseline over time in mean grip strength (non-dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Baseline to 12 weeks
|
|
Stage B: Time to First Adjusted INCAT Disability Scale Score Deterioration Relative to Baseline
Lasso di tempo: Up to 52 weeks
|
Time to first adjusted INCAT disability scale score deterioration relative to Stage B baseline will be reported. |
Up to 52 weeks
|
|
Stage B: Time to First Switch to Intravenous Immunoglobulin (IVIg) or Other Standard of Care (SoC) as a Result of Investigator-assessed Lack of Efficacy as Confirmed by an Independent RAC Relative to Baseline
Lasso di tempo: Up to 52 weeks
|
Time to first switch to IVIg or other SoC as a result of investigator-assessed lack of efficacy as confirmed by an independent Relapse Adjudication Committee (RAC) relative to Stage B baseline will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in Adjusted INCAT Disability Score
Lasso di tempo: Up to 52 weeks
|
Change from Stage B baseline over time in adjusted INCAT disability score will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in MRC Muscle Grading Scale Sum Score
Lasso di tempo: Up to 52 weeks
|
Change from Stage B baseline over time in MRC Muscle Grading Scale Sum score will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in I-RODS Centile Score
Lasso di tempo: Up to 52 weeks
|
Change from Stage B baseline over time in I-RODS centile score will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in Mean Grip Strength (Dominant Hand)
Lasso di tempo: Up to 52 weeks
|
Change from Stage B baseline over time in mean grip strength (dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in Mean Grip Strength (Non-Dominant Hand)
Lasso di tempo: Up to 52 weeks
|
Change from Stage B baseline over time in mean grip strength (non-dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Up to 52 weeks
|
|
Stage B: Number of Participants with Binary Response Endpoint Satisfying all 4 Conditions: a) An Improved Adjusted INCAT Disability Score Compared to Baseline; b) Not Relapsing; c) Not Switching to SoC; d) Not Discontinuing Treatment
Lasso di tempo: Up to 52 weeks
|
Number of participants with Binary response endpoint satisfying all 4 conditions: a) an improved adjusted INCAT Disability Score compared to Stage B baseline; b) not relapsing; c) not switching to SoC; d) not discontinuing treatment, will be reported. |
Up to 52 weeks
|
|
Percentage of Participants with Treatment-emergent Adverse Events (TEAEs)
Lasso di tempo: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Percentage of Participants with Serious Adverse Events (SAEs)
Lasso di tempo: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
SAE is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Change in Electrocardiogram (ECG) Values Over Time
Lasso di tempo: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with change in ECG values over time will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Change in Vital Signs Values Over Time
Lasso di tempo: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with change in vital signs values over time will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Change in Clinical Laboratory Values Over Time
Lasso di tempo: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with change in clinical laboratory values over time will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Clinically Significant ECG Abnormalities
Lasso di tempo: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with clinically significant ECG abnormalities will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Clinically Significant Vital Signs Abnormalities
Lasso di tempo: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with clinically significant vital signs abnormalities will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Clinically Significant Clinical Laboratory Abnormalities
Lasso di tempo: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with clinically significant clinical laboratory abnormalities will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Percentage of Participants with Suicidal Ideation or Suicidal Behavior based on the Columbia-Suicide Severity Rating Scale (C-SSRS)
Lasso di tempo: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Percentage of participants with suicidal ideation or suicidal behavior based on the C-SSRS will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Serum Nipocalimab Concentrations Over Time in Participants Receiving Active Study Intervention
Lasso di tempo: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Serum nipocalimab concentrations over time in participants receiving active study intervention will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Anti-drug Antibodies (ADA) to Nipocalimab
Lasso di tempo: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with ADA to Nipocalimab will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Titers of ADA to Nipocalimab
Lasso di tempo: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Titers of ADA to nipocalimab will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Neutralizing Antibodies (NAb) to Nipocalimab
Lasso di tempo: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with NAb to Nipocalimab will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Change from Baseline in Total Serum Immunoglobulin (IgG) Concentrations Levels Over Time
Lasso di tempo: Stage A: Baseline to 12 weeks; Stage B: Baseline up to 52 weeks
|
Change from baseline in total serum IgG concentrations levels over time will be reported. |
Stage A: Baseline to 12 weeks; Stage B: Baseline up to 52 weeks
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema nervoso
- Processi patologici
- Malattie neuromuscolari
- Malattia cronica
- Attributi della malattia
- Malattie autoimmuni
- Malattie del sistema immunitario
- Malattie del sistema nervoso periferico
- Malattie autoimmuni del sistema nervoso
- Malattie demielinizzanti
- Polineuropatie
- Poliradicoloneuropatia
- Condizioni patologiche, segni e sintomi
- Poliradiculoneuropatia, demielinizzante infiammatoria cronica
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- CR109195
- 80202135CDP3001 (Altro identificatore: Janssen Research & Development, LLC)
- 2021-003234-37 (Numero EudraCT)
- 2023-508425-28-00 (Identificatore di registro: EUCT number)
- 2023 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .